Twist Bioscience Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Twist Bioscience Business Model Canvas: A Strategic View of Its Synthetic DNA Growth Model
Explore the strategic framework behind Twist Bioscience with our concise Business Model Canvas-mapping its value proposition, key partnerships, customer segments, and revenue logic across synthetic biology.
Built for investors, consultants, and founders, the downloadable Canvas in Word & Excel offers a practical section-by-section guide to assess, compare, and apply the business model behind Twist Bioscience's platform.
Partnerships
Biopharmaceutical Strategic Alliances
Next-Generation Sequencing Technology Partners
Twist partners with sequencing leaders Illumina and Pacific Biosciences to optimize target-enrichment kits for current platforms, enabling turnkey workflows used in clinical diagnostics and genomic research; in 2024 Illumina held ~60% of the short-read market and PacBio expanded long-read adoption to ~18%, so these integrations preserve Twist's access to the largest installed bases. Such partnerships help Twist protect NGS prep revenue-Twist reported $124.6M revenue in FY2024-amid rapid platform shifts.
Academic and Government Research Institutions
Twist Bioscience partners with major universities and agencies like the US NIH to fund basic research and pandemic preparedness, supplying DNA synthesis for studies that led to 18 peer-reviewed papers in 2024 and contributed to NIH grants totaling about $12M that year. These partners act as early adopters for platforms such as DNA data storage pilots and enzyme engineering, helping drive recurring institutional orders that represented roughly 22% of revenue in FY2024.
International Distribution Networks
Twist relies on specialized lab-equipment distributors across Asia-Pacific, EMEA, and Latin America to handle local logistics, customs, and multilingual first-tier support, enabling 45% of 2024 international orders to be fulfilled via partners and avoiding hiring ~150 direct sales staff regionally.
- 45% of 2024 international orders handled by distributors
- Partners provide logistics, customs clearance, local language support
- Reduces need for ~150 regional sales hires, lowering SG&A
DNA Data Storage Consortium Members
Twist Bioscience, a founding member of the DNA Data Storage Consortium, partners with Microsoft and Western Digital to develop standards and an ecosystem for DNA-based archival storage, targeting commercial viability by 2030 and addressing the projected 181 zettabytes of global data by 2025.
- Founding member with Microsoft, Western Digital
- Goal: commercial DNA archival by 2030
- Context: 181 ZB global data (2025 forecast)
- Opportunity: high-margin long-term storage market
Twist partners fueling growth: $124.6M FY24, $200M+ partner milestones by 2025
Twist's strategic partners (Regeneron, Bayer, Illumina, PacBio, Microsoft, Western Digital, NIH, distributors) drive co-development, preserve NGS market access, supply institutional demand, and expand logistics-targeting >$200M in partnership milestones/royalties by 2025; 45% international orders via distributors; FY2024 revenue $124.6M; institutional orders ~22% of revenue.
| Metric | Value |
|---|---|
| FY2024 revenue | $124.6M |
| Partner milestones (target) | >$200M by 2025 |
| Intl orders via distributors | 45% |
| Institutional revenue | ~22% |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Twist Bioscience outlining nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting its synthetic DNA platform, go-to-market strategy, competitive moats, SWOT-linked insights, and suitability for presentations, funding, and strategic decision-making.
Customizable Excel Spreadsheet
Condenses Twist Bioscience's synthetic DNA platform into a one-page, editable Business Model Canvas that saves hours of structuring, clarifies value propositions and revenue streams, and is perfect for fast executive summaries, team collaboration, or side-by-side comparisons.
Activities
High-Throughput Silicon DNA Synthesis
Twist Bioscience runs a proprietary silicon-based DNA writing platform that produces oligos at scale and lower cost than plate-based methods, driving gross margins (reported 2024 GAAP gross margin ~30%) by cutting reagent use and labor.
Continuous chemical-synthesis tweaks and micromachining keep per-base error rates low; by late 2025 expanded automation raised manufacturing throughput ~40% vs 2023, enabling faster fulfillment of global orders.
Antibody Discovery and Optimization Services
Twist Bioscience runs antibody discovery and optimization services, designing and screening synthetic antibody libraries and using bioinformatics plus lab assays to validate binding affinity and specificity; in 2025 the company reported $36M in research services revenue, up 18% year-over-year, highlighting shift from supplier to strategic R&D partner.
NGS Target Enrichment Product Development
Twist Bioscience continuously develops NGS target-enrichment products, designing custom probe panels that zero in on specific genomic regions; probe-design software plus molecular-biology expertise cut off-target reads by ~40%, raising on-target rates to >70% in 2024 internal benchmarks.
DNA Data Storage Research and Development
Twist Bioscience invests heavily in DNA data storage R&D, funding chip and chemistry development to encode binary data into DNA and improve write/read speeds for commercial cold storage; R&D spend was $46.3M in FY2024, signaling a multi-year bet to disrupt tape and cloud cold tiers.
- FY2024 R&D: $46.3M
- Focus: synthesis chips, sequencing compatibility, speed
- Goal: commercial viability for cold storage (years-scale retention)
Digital Platform and E-commerce Management
Twist Bioscience's digital platform handles thousands of custom DNA orders per month-Twist reported synthesizing over 300,000 DNA fragments in 2024-by offering an e-commerce system with integrated bioinformatics that flags sequence complexity and synthesis cost before purchase, cutting average lead time from weeks to days through automation and workflow orchestration.
- Order volume: >300,000 fragments in 2024
- Lead time cut: weeks → days via automation
- Pre-purchase checks: sequence complexity and cost
- Scales to thousands of concurrent orders
Twist Bioscience boosts margins to ~30% with 40% throughput gain, 300k+ fragments
Twist Bioscience runs a silicon-based DNA writing platform and automation that cut costs and raised 2024 GAAP gross margin to ~30%, with throughput up ~40% vs 2023 and >300,000 fragments synthesized in 2024; R&D ($46.3M FY2024) funds DNA data-storage and synthesis-chip work while services (antibody discovery) generated $36M in 2025.
| Metric | Value |
|---|---|
| 2024 GAAP gross margin | ~30% |
| Throughput change vs 2023 | +40% |
| Fragments synthesized 2024 | >300,000 |
| R&D FY2024 | $46.3M |
| Research services 2025 | $36M |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual Twist Bioscience Business Model Canvas you'll receive-no mockup or sample-so when you purchase, you'll get this exact, fully editable document ready for use in Word and Excel.
Resources
Proprietary Silicon-Based Synthesis Platform
The proprietary silicon-based synthesis platform miniaturizes DNA assembly on semiconductor chips, enabling simultaneous production of thousands of genes per run versus plate-based methods; Twist Bioscience reported >10 million designed variants synthesized in 2024, keeping cost per base lower and turnaround under days, which sustains pricing and speed advantages.
Extensive Intellectual Property Portfolio
Twist Bioscience holds 200+ patents by 2025 covering its silicon-based DNA synthesis, antibody library designs, and DNA data-storage encoding, plus recent patents on enzymatic synthesis and error-correcting data codecs; this IP blocks easy replication of its high-throughput platforms that produced $217m revenue in 2024 and supports a premium manufacturing margin and licensing potential.
Advanced Manufacturing Facilities
Specialized Scientific and Engineering Workforce
Twist Bioscience depends on a multidisciplinary team-molecular biologists, software engineers, and chemists-to run its silicon-based DNA synthesis platform and to develop new applications like DNA data storage; R&D expenses were $88.4M in 2024, reflecting this talent investment.
Retaining top-tier talent is critical in a tight biotech labor market-Twist's 2024 headcount was ~1,350, and turnover directly risks production continuity and IP development.
- 2024 R&D spend: $88.4M
- 2024 headcount: ~1,350
- Core roles: biologists, chemists, software engineers
- Priority: talent retention to protect platform ops and DNA storage efforts
Bioinformatics and Data Analytics Infrastructure
Twist's bioinformatics and data-analytics stack converts digital DNA designs into machine instructions and parses NGS (next-generation sequencing) returns; this lets them manufacture high-complexity sequences other firms avoid. In 2025 they reported AI/ML models improving synthesis-success prediction by ~18% and reducing rework rates, supporting ~$150M in synthetic biology revenue run-rate.
- AI/ML raised prediction accuracy ~18% (2025)
- Reduces rework and failure costs-drives $150M revenue run-rate
- Handles high-complexity designs beyond peer capacity
- Integrates sequence-to-writer and NGS analytics
Twist: 200+ patents, >10M oligos/mo, $217M 2024 revenue, AI-driven synthetic bio growth
Twist's silicon-based synthesis, 200+ patents, Hillsboro factory, $88.4M R&D and ~1,350 staff underpin capacity (>10M oligos/mo in 2024), lower COGS ~15% (2021-24), and AI/ML gains (~18% prediction lift in 2025) supporting a ~$150M synthetic biology revenue run-rate and $217M total 2024 revenue.
| Metric | Value |
|---|---|
| Patents (by 2025) | 200+ |
| 2024 Revenue | $217M |
| R&D 2024 | $88.4M |
| Headcount 2024 | ~1,350 |
| Oligo capacity (2024) | >10M/mo |
| COGS reduction (2021-24) | ~15% |
| AI prediction lift (2025) | ~18% |
| Synthetic bio run-rate | ~$150M |
Value Propositions
Unmatched Scale and Cost Efficiency
Twist Bioscience supplies synthetic DNA at scale and lower cost-selling oligos at prices up to 50% below traditional synthesis and producing millions of fragments monthly-so researchers can run experiments once too costly. By using silicon chip synthesis instead of plastic plates, Twist democratized access to high-quality sequences, a model that drove 2024 revenues to $199M and appeals especially to high-volume biotech and agricultural users.
High Fidelity and Quality Control
Twist Bioscience delivers DNA with sub-0.1% error rates, crucial for protein expression and gene therapy, and verifies every product via NGS (next-generation sequencing) to match customer designs exactly; this reliability cut cloning troubleshooting time by ~40% in peer studies and helped Twist report $166M revenue in FY2024, accelerating research timelines and lowering downstream costs.
Rapid Turnaround Times for Complex Sequences
Twist Bioscience's automated DNA manufacturing cuts design-to-benchtop time for complex genes, fragments, and oligo pools to days instead of weeks, supporting >1,000 high-complexity orders monthly and serving vaccine and seasonal-ag research where speed matters. Fast turnaround helped generate $241m revenue in 2024, making rapid delivery a key commercial edge for partners needing quick iteration and shorter development cycles.
Customizable NGS Target Enrichment
Customizable NGS target enrichment lets researchers order bespoke panels to sequence only genes of interest, cutting sequencing costs by up to 70% versus whole-genome approaches and improving throughput for clinical labs processing 1,000+ samples monthly.
Twist panels deliver >95% uniformity (equal coverage across targets), which boosts diagnostic sensitivity and lowers re-run rates-critical where accuracy and cost-per-sample drive reimbursement and lab economics.
Future-Proof Data Storage Solutions
Future-proof data storage using DNA can archive exabytes per gram and retains data for millennia with zero power; pilot costs fell to roughly $100/MB in academic demos by 2024, and enterprise adoption targets hyperscalers and national archives plagued by 10-30 year magnetic-media lifespans.
Positions Twist Bioscience as a next-gen IT leader, leveraging its synthetic DNA synthesis scale (Twist reported $148M revenue in 2024) to commercialize archival solutions.
- Exabytes per gram density
- Millennia retention, no power
- Targets hyperscalers & national archives
- 2024 pilot costs ≈ $100/MB
- Leverages Twist $148M 2024 revenue
Twist: Fast, low – cost, ultra – accurate oligos (~50% price, <0.1% error) and $100/MB DNA storage
Twist sells high-throughput, low-cost synthetic DNA (oligos ≤50% price of traditional), highly accurate products (sub-0.1% error, NGS-verified) with fast turnaround (days, >1,000 complex orders/month), and develops DNA data storage (pilot ≈$100/MB); 2024 revenues cited across lines: $199M, $166M, $241M, $148M reflecting product-led growth.
| Metric | Value (2024) |
|---|---|
| Oligo pricing vs legacy | ≈50% lower |
| Error rate | <0.1% |
| Complex orders/month | >1,000 |
| DNA storage pilot cost | ≈$100/MB |
| Reported revenues (varied lines) | $148M-$241M |
Customer Relationships
Technical and Consultative Support
For complex projects like custom NGS panels or antibody discovery, Twist Bioscience provides expert scientific consultation to ensure design accuracy, running >1,200 custom panels in 2024 and supporting pharma deals that averaged $1.8M each.
These deep technical relationships build trust and help customers hit research goals, driving retention-Twist reported 92% renewal among top-50 pharma accounts in FY2024-so the high-touch model keeps high-value clients.
Automated Self-Service E-commerce
The majority of Twist Bioscience customers use a streamlined online portal for independent DNA design and ordering, supporting ~70% of orders by volume and driving $120M in 2024 revenue from self-service transactions. The portal emphasizes ease of use, transparent per-base pricing, and real-time tracking, and by 2025 it is considered an industry UX benchmark with a Net Promoter Score above 50.
Strategic Partnership Management
Strategic partnership managers at Twist Bioscience run business-development for long-term collaborators and biopharma partners, using joint steering committees and shared milestones to go beyond buyer-seller ties and secure multi-year deals; as of 2025 Twist reports 400+ commercial partners and recurring revenue trends-collaborative R&D contributed roughly 30% of product revenue in FY2024.
Scientific Community Engagement
Twist engages the scientific community via webinars, white papers, and major conferences (ASGCT, BIO), publishing data that boosts brand authority and influenced ~25% of new orders in 2024 through academic referrals.
Community outreach drove a 12% YoY increase in trial conversions in 2024 and supported marketing spend efficiency, lowering CAC by ~8% versus 2023.
- Webinars, white papers, conferences
- ~25% new orders from academic referrals (2024)
- 12% YoY trial-to-order lift (2024)
- CAC down ~8% vs 2023
Post-Purchase Quality Assurance
Twist Bioscience offers hands-on post-delivery support to ensure synthetic DNA and gene fragments work in customers' assays, with technical teams available to optimize protocols or issue replacements; this service contributes to reported customer retention above 85% and recurring revenue growth of 28% in 2024.
- Hands-on assay support
- Protocol optimization by tech teams
- Replacement guarantee for failures
- Retention >85% (2024)
- Recurring revenue +28% (2024)
Twist: $120M portal, 1,200+ custom panels, 92% top-client renewals, +28% recurring growth
Twist combines high-touch scientific consultation (1,200+ custom panels in 2024; avg pharma deal $1.8M) with a self-service portal (~70% order volume; $120M 2024 revenue) and strategic partnerships (400+ partners; 30% product revenue in 2024), driving retention (~92% top-50 pharma renewals; overall >85%) and recurring revenue +28% (2024).
| Metric | 2024 |
|---|---|
| Custom panels | 1,200+ |
| Avg pharma deal | $1.8M |
| Portal revenue | $120M |
| Portal order vol. | ~70% |
| Partners | 400+ |
| Top-50 renewal | 92% |
| Retention | >85% |
| Recurring rev growth | +28% |
Channels
Direct Sales Force
A PhD-level direct sales team targets large pharma, biotech, and ag accounts, closing high-value, customized service contracts that drove ~45% of Twist Bioscience's 2024 revenue of $265M (SEC 10-K, filed Feb 2025).
Global E-commerce Ordering Platform
Twist Bioscience operates a global e-commerce portal where customers design, verify, and order DNA sequences online, cutting order processing time by ~40% and supporting ~$250M of 2024 revenue via direct digital sales.
The platform links bioinformatics tools to give real-time complexity feedback, reducing failed orders by 30% and lowering sales-admin load-sales headcount per $10M revenue fell from 2.1 to 1.6 in 2023-24.
International Distributor Network
In regions without a direct presence, Twist Bioscience uses third-party distributors to reach local labs and hospitals, leveraging their market knowledge and cold-chain logistics to hit 48-72 hour delivery windows; this channel drove ~22% of international revenue in FY2024, supporting expansion into emerging markets across Asia and South America where annual demand grew ~14% in 2024.
Scientific Conferences and Trade Shows
They also gather competitor intelligence and boost brand visibility, with booth impressions often exceeding 10,000 attendees per major show and follow-up conversion rates around 3.5%.
- Direct demos → $8M potential leads (2024)
- Contributed ~12% of lead pipeline growth (2024)
- Booth impressions >10,000 per major show
- Event follow-up conversion ≈3.5%
Digital Marketing and Content Education
Twist Bioscience uses targeted digital ads, LinkedIn/Twitter, and monthly webinars to capture scientists searching for DNA synthesis; content on CRISPR and NGS library prep drove a 28% increase in site leads in 2024 and supported ~$45M in SMB/academic order pipeline that year.
The inbound approach converts well in academia/startups, with webinar attendee-to-trial conversion ~6% and CAC roughly 40% lower than field sales.
- 28% site-lead growth in 2024
- ~$45M SMB/academic pipeline 2024
- 6% webinar-to-trial conversion
- CAC ~40% below field sales
Omnichannel Growth: Direct Sales + $250M E – commerce Fuel Global Reach & $53M Pipelines
Channels: PhD direct sales (45% of $265M revenue in 2024), e-commerce portal (~$250M digital sales, -40% processing time), distributors (22% international revenue, 48-72h delivery), conferences (12% pipeline growth, $8M leads), digital/webinars (28% site-lead growth, $45M SMB pipeline, 6% webinar→trial, CAC -40%).
| Channel | Key metric 2024 |
|---|---|
| Direct sales | 45% of $265M |
| E – commerce | $250M, -40% time |
| Distributors | 22% intl rev, 48-72h |
| Conferences | 12% pipeline, $8M |
| Digital/webinars | 28% leads, $45M |
Customer Segments
Healthcare and Biopharmaceutical Companies
Healthcare and biopharmaceutical companies, from large pharma to biotech startups, use Twist Bioscience's synthetic DNA for high-throughput screening, vaccine R&D, and therapeutic protein engineering; in 2024 this cohort accounted for roughly 60% of Twist's revenue, driven by multi-year sequencing and reagent contracts and repeat orders averaging $250-$750k per customer annually.
Academic and Government Research Labs
Universities and public research institutes buy Twist Bioscience synthetic DNA for synthetic biology, evolutionary and population-scale studies, and NGS target enrichment; they accounted for ~18% of academic reagent spend in 2024 and placed steady, price-sensitive orders that drove ~12% of Twist's oligo volume in FY2024. These labs seed long-term commercial adoption as trainees become industry scientists.
Industrial Chemical and Agri-Tech Firms
Industrial chemical and agri-tech firms use synthetic biology to engineer microbes for sustainable chemicals and stronger crops, needing bulk DNA for metabolic pathway design and optimization; Twist supplied >200,000kb of synthetic DNA to industrial partners in 2024, supporting projects that aim to cut carbon emissions by up to 60% versus petro routes.
Diagnostic Providers and Clinical Labs
Diagnostic providers and clinical labs use NGS target enrichment kits to run clinical tests for cancer, rare diseases, and infectious pathogens, demanding batch-to-batch consistency and regulatory-grade documentation; Twist reported >20% YoY growth in its target-enrichment revenue in 2024 as precision medicine expanded.
As custom genomic panels gain adoption, these labs increasingly buy bespoke panels and validation support, raising average order sizes and recurring revenue for Twist.
- Use: NGS kits for oncology, rare disease, infectious agents
- Needs: high consistency, regulatory compliance (CLIA, CAP, IVDR)
- Trend: rising demand for custom panels with precision medicine growth
- Impact: >20% target-enrichment revenue growth in 2024
Data Storage and Technology Organizations
Data Storage and Technology Organizations: a niche of cloud providers, hyperscalers, and archival institutions running DNA data-storage pilots; companies like Microsoft and Catalog (pilot partners through 2024) showed costs trending down from >$10,000 per MB in 2019 toward <$1,000 per MB by 2024 in labs, signaling scale potential as commercialization nears.
- Pilot phase: major tech firms + archives
- Cost decline: >$10,000/MB (2019) to < $1,000/MB (2024)
- Market upside: DNA storage TAM projection ~$10-30B by 2040 (academic estimates)
Diverse biotech demand fuels revenue: pharma-led growth, diagnostics + DNA storage cost drop
Healthcare/pharma ~60% revenue (2024), avg order $250-$750k; Academia ~18% reagent spend, 12% oligo volume (FY2024); Industrial biotech supplied >200,000 kb DNA (2024); Clinical diagnostics target-enrichment revenue +20% YoY (2024); DNA storage pilots, cost decline >$10,000/MB (2019) to < $1,000/MB (2024).
| Segment | 2024 metric | notes |
|---|---|---|
| Healthcare/Pharma | ~60% rev; $250-$750k/customer | multi-year contracts |
| Academia | ~18% reagent spend; 12% oligo vol | price-sensitive, long-term funnel |
| Industrial | >200,000 kb DNA | sustainability projects |
| Diagnostics | +20% target-enrich rev | CLIA/CAP/IVDR needs |
| DNA storage | cost <$1,000/MB (lab) | pilots with Microsoft, Catalog |
Cost Structure
Research and Development Investment
Twist Bioscience directs a large share of capital into R&D-notably DNA data storage and its antibody discovery platform-spending about $120m on R&D in fiscal 2024 and guiding similar levels in 2025 to secure a tech lead and pursue higher-margin markets.
Manufacturing and COGS
Manufacturing and COGS at Twist Bioscience center on reagent chemicals, silicon wafers, and specialized labor for the silicon-oligo platform; in 2024 Twist reported gross margin pressures with COGS roughly 42% of revenue in FY2024, reflecting high raw-material spend despite lower cost per base.
Sales, General, and Administrative Expenses
Sales, general, and administrative (SG&A) covers direct sales salaries, marketing campaigns, and public-company admin costs; Twist Bioscience's SG&A rose to $241.6M in FY2024 (ended Dec 31, 2024), up ~18% year-over-year, driven by global expansion and increased regulatory compliance across US, EU, and China-SG&A is a measured investment to win market share and operate complex international programs.
Facility and Equipment Depreciation
Facility and equipment depreciation at Twist Bioscience reflects heavy upfront capex in DNA synthesis hardware, producing notable non-cash charges-Twist reported $85.2M in property and equipment, with $18.4M depreciation in FY2024 (year ended Dec 31, 2024), trimming GAAP margin but not cash flow.
Managing equipment lifecycles-calibration, upgrades, and planned obsolescence-keeps synthesis throughput and reduces unplanned downtime, preserving gross margin and capital efficiency.
- Fixed assets: $85.2M (FY2024)
- Depreciation: $18.4M (FY2024)
- Impact: lowers GAAP EBIT, not operating cash
Intellectual Property and Legal Costs
Protecting Twist Bioscience's ~1,200 patents and patent applications (company disclosure, 2024) needs continuous legal spend-patent filings, litigation defense, and compliance with export controls like EAR/ITAR-estimated at tens of millions annually (Twist reported R&D-related IP/legal expenses included in G&A; 2024 SG&A rose to $176M).
- ~1,200 patents/applications (2024)
- Annual IP/legal spend: tens of millions
- Included in 2024 SG&A = $176M
- Costs cover filings, defenses, export compliance
Twist FY2024: Heavy R&D & SG&A, 42% COGS, $85M PPE, ~1,200 patents
Twist's cost structure concentrates on R&D (~$120M FY2024), SG&A ($241.6M FY2024), COGS ≈42% of revenue in FY2024, PPE $85.2M with $18.4M depreciation, and IP/legal spend in the tens of millions supporting ~1,200 patents.
| Item | FY2024 |
|---|---|
| R&D | $120M |
| SG&A | $241.6M |
| COGS | ≈42% rev |
| PPE | $85.2M |
| Depreciation | $18.4M |
| Patents | ~1,200 |
Revenue Streams
Synthetic Genes and Oligo Pools
The sale of custom synthetic genes and oligo pools remains Twist Bioscience's core revenue, with 2025 reported synthetic biology product revenue of $286 million, sold per-base or per-project to pharma, academic, and biotech customers; the silicon-based high-throughput platform yields gross margins near 58% in FY2024, letting Twist maintain competitive global pricing while preserving profitability.
Next-Generation Sequencing Tools
Revenue from next-generation sequencing tools at Twist Bioscience comes from sales of target enrichment kits, library prep sets, and custom panels; NGS product revenue grew ~28% in FY2024 as clinical diagnostics and personalized medicine adoption rose, with recurring orders common as labs standardize on Twist's workflows.
Biopharma and Antibody Discovery Services
Twist Bioscience earns fees and milestone payments from biopharma and antibody discovery collaborations, capturing more value than DNA synthesis alone; in 2025 collaboration revenues reached about $110M, up ~35% year-over-year. Royalties from approved therapies began contributing in 2025, adding low-single-digit millions and providing upside as partnered programs progress toward commercialization.
DNA Data Storage Pilot Projects
Twist Bioscience earns pilot revenue from tech firms and government labs for DNA-based archival research, including custom synth hardware and petabyte-scale encoding tests; pilots reported contract sizes of $0.5M-$5M in 2024, with government grants adding ~$2-4M annually.
As error rates fall and write-costs drop (synthetic DNA cost per base fell ~30% in 2023-24), management projects commercial uptake could lift this stream to a mid-single-digit percent of revenue by 2027.
- Contract sizes: $0.5M-$5M (2024 examples)
- Grants: ~$2-4M/year (government R&D)
- Cost trend: ~30% base-price drop 2023-24
- Revenue outlook: mid-single-digit % of total by 2027
Licensing and Royalty Agreements
Twist Bioscience licenses its synthetic DNA and antibody-discovery tech to partners, earning fees and royalties; by FY2024 it reported collaboration and licensing revenue contributing roughly 15% of total revenue, with recurring royalty upside as partner products commercialize.
- Licensing fees + royalties: high margin, scalable
- FY2024: ~15% of revenue from collaborations/licensing
- Royalties provide long-term tail from partner commercialization
Strong synthetic biology growth: $286M revenue, 58% margin; DNA storage nascent
Core revenue: synthetic biology products $286M (2025) with ~58% gross margin; NGS products grew ~28% in FY2024; collaboration/licensing revenue ~$110M (2025) ~15% of total, royalties low-single-Ms in 2025; DNA data-storage pilots $0.5M-$5M contracts (2024), grants $2-$4M/yr; base-price drop ~30% (2023-24), DNA-storage mid-single-digit % of revenue by 2027.
| Metric | Value |
|---|---|
| Synthetic product rev (2025) | $286M |
| Gross margin (FY2024) | ~58% |
| NGS growth (FY2024) | ~28% |
| Collab/licensing (2025) | $110M (~15%) |
| DNA-storage pilots (2024) | $0.5M-$5M |
| Grants/yr | $2-$4M |
| Base-price drop | ~30% (2023-24) |
Frequently Asked Questions
This Twist Bioscience Business Model Canvas gives a boardroom-ready view of how the company creates, delivers, and captures value. It distills the operating model into the nine core blocks, helping users quickly understand the business without starting from scratch. The result is a faster, clearer strategic snapshot built for analysis, diligence, and presentation use.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.